SCHEMBL11945587

SCHEMBL11945587

CC(C)S(=O)(=O)N1CCN(c2cn[nH]c(=O)c2Cl)CC1

nearest known ligand 0.64

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.64
ALDH1A1 P00352 4/20 0.59
TIPARP Q7Z3E1 6/20 0.49
TRPC5 Q9UL62 7/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11916248 0.79 POLB (1.00) POLBALDH1A1TIPARPTRPC5
SCHEMBL11945586 0.77 CYP17A1 (0.43) POLBALDH1A1TIPARPTRPC5
SCHEMBL11946093 0.77 TRPC5 (0.39) POLBALDH1A1TIPARPTRPC5
SCHEMBL17738866 0.75 ALDH1A1 (0.50) POLBALDH1A1
SCHEMBL20818330 0.74 POLB (0.76) POLBALDH1A1TIPARPTRPC5
SCHEMBL14081025 0.74 POLB (0.76) POLBALDH1A1TIPARPTRPC5
SCHEMBL20817859 0.73 POLB (0.78) POLBALDH1A1TIPARPTRPC5
SCHEMBL20817860 0.73 POLB (0.78) POLBALDH1A1TIPARPTRPC5
SCHEMBL20818061 0.73 POLB (0.78) POLBALDH1A1TIPARPTRPC5
SCHEMBL20818405 0.73 POLB (0.68) POLBALDH1A1TIPARPTRPC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137179-B1 PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS MERCK SHARP & DOHME (US) 2015-09-02 EP disclosed
EP-2586778-A2 Pyridazinone derivatives useful as glucan synthase inhibitors Merck Sharp & Dohme Corp. (US) 2013-05-01 EP disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
WO-2008115381-A1 PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA POLB 1088/4885ALDH1A1 2437/4885TIPARP 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.